Legend Biotech Reports 100% Response Rates in Eight LB2501 Patients

Legend Biotech said ASH 2026 abstracts report 100% response and complete response rates among eight patients at LB2501 dose level 2, with responses lasting up to five months. The abstracts also report a 1.6% CITADEL IEC-parkinsonism rate with preemptive steroids versus 2.9% in historical data.